Annexin A10 (ANXA10) is a member of the annexin family, calcium-dependent phospholipid-binding proteins implicated in diverse cellular processes, including membrane trafficking, signal transduction, and apoptosis. Unlike other annexins, ANXA10 exhibits tissue-specific expression, predominantly localized in the gastric mucosa, skin, and gastrointestinal tract. Its biological roles remain less characterized but are thought to involve cell differentiation and tumorigenesis regulation.
ANXA10 antibodies are immunodetection tools targeting this protein, widely used in research to study its expression, localization, and function. These antibodies are critical in techniques like immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF). Notably, ANXA10 has gained attention as a potential biomarker in oncology. Studies link its overexpression to specific cancers, particularly gastric and colorectal adenocarcinomas, where it may serve as a diagnostic or prognostic indicator. For example, ANXA10 is highly expressed in a subset of gastric cancers with poor differentiation, suggesting its utility in tumor subtyping.
Commercially available ANXA10 antibodies are typically monoclonal or polyclonal, validated for specificity and sensitivity across human and murine samples. Researchers must optimize protocols due to potential cross-reactivity with other annexins or tissue-specific isoforms. Recent investigations also explore ANXA10's role in drug resistance and its interaction with signaling pathways like Wnt/β-catenin, highlighting its therapeutic relevance.
In summary, ANXA10 antibodies are vital for elucidating the protein’s pathophysiological roles, particularly in cancer biology, while advancing diagnostic and therapeutic strategies.